Last reviewed · How we verify
Inflammatory biomarkers dosage "Hypothermia Arm"
Inflammatory biomarkers dosage "Hypothermia Arm" is a Biologic drug developed by Centre Hospitalier Departemental Vendee. It is currently in Phase 3 development for Therapeutic hypothermia in acute conditions (likely cardiac arrest, traumatic brain injury, or stroke based on typical hypothermia trial designs).
This is a clinical trial arm measuring inflammatory biomarkers in hypothermia-treated patients, not a drug with a defined pharmacological mechanism.
This is a clinical trial arm measuring inflammatory biomarkers in hypothermia-treated patients, not a drug with a defined pharmacological mechanism. Used for Therapeutic hypothermia in acute conditions (likely cardiac arrest, traumatic brain injury, or stroke based on typical hypothermia trial designs).
At a glance
| Generic name | Inflammatory biomarkers dosage "Hypothermia Arm" |
|---|---|
| Sponsor | Centre Hospitalier Departemental Vendee |
| Modality | Biologic |
| Therapeutic area | Critical Care / Neuroprotection |
| Phase | Phase 3 |
Mechanism of action
The 'Hypothermia Arm' refers to a study cohort receiving therapeutic hypothermia as an intervention, with inflammatory biomarkers being measured as outcome variables to assess the anti-inflammatory effects of temperature reduction. This is a clinical trial design element rather than a pharmaceutical agent with a specific molecular mechanism of action.
Approved indications
- Therapeutic hypothermia in acute conditions (likely cardiac arrest, traumatic brain injury, or stroke based on typical hypothermia trial designs)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inflammatory biomarkers dosage "Hypothermia Arm" CI brief — competitive landscape report
- Inflammatory biomarkers dosage "Hypothermia Arm" updates RSS · CI watch RSS
- Centre Hospitalier Departemental Vendee portfolio CI
Frequently asked questions about Inflammatory biomarkers dosage "Hypothermia Arm"
What is Inflammatory biomarkers dosage "Hypothermia Arm"?
How does Inflammatory biomarkers dosage "Hypothermia Arm" work?
What is Inflammatory biomarkers dosage "Hypothermia Arm" used for?
Who makes Inflammatory biomarkers dosage "Hypothermia Arm"?
What development phase is Inflammatory biomarkers dosage "Hypothermia Arm" in?
Related
- Manufacturer: Centre Hospitalier Departemental Vendee — full pipeline
- Therapeutic area: All drugs in Critical Care / Neuroprotection
- Indication: Drugs for Therapeutic hypothermia in acute conditions (likely cardiac arrest, traumatic brain injury, or stroke based on typical hypothermia trial designs)
- Compare: Inflammatory biomarkers dosage "Hypothermia Arm" vs similar drugs
- Pricing: Inflammatory biomarkers dosage "Hypothermia Arm" cost, discount & access